Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection.
Ampuero J, del Campo JA, Rojas L, García-Lozano RJ, Buti M, Solá R, Forns X, Moreno-Otero R, Andrade R, Diago M, Salmerón J, Rodrigo L, Pons JA, Navarro JM, Calleja JL, García-Samaniego J, García-Valdecasas M, Rojas Á, Millán R, González-Escribano MF, Romero-Gómez M. Ampuero J, et al. Among authors: sola r. Genes Immun. 2015 Jul-Aug;16(5):297-300. doi: 10.1038/gene.2015.14. Epub 2015 Apr 30. Genes Immun. 2015. PMID: 25928882
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
Salmerón J, Diago M, Andrade R, Pérez R, Solá R, Romero M, de la Mata M, Granados R, Ruiz-Extremera A, Muñoz de Rueda P. Salmerón J, et al. Among authors: sola r. J Viral Hepat. 2007 Feb;14(2):89-95. doi: 10.1111/j.1365-2893.2006.00771.x. J Viral Hepat. 2007. PMID: 17244248 Clinical Trial.
Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.
Pérez R, Jiménez M, Crespo J, Diago M, Enríquez J, Vaquero P, Solá R, Olcoz JL, Romero M, Salmerón J, Blanco MI, Oña M, Melón S, Rodrigo L; Grupo Inter-Hospitalario Español. Pérez R, et al. Among authors: sola r. J Viral Hepat. 2003 Nov;10(6):437-45. doi: 10.1046/j.1365-2893.2003.00461.x. J Viral Hepat. 2003. PMID: 14633177 Clinical Trial.
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
Diago M, Olveira A, Solá R, Romero-Gómez M, Moreno-Otero R, Pérez R, Salmerón J, Enríquez J, Planas R, Gavilán JC, Del Olmo J, Uribarrena R, Sillero C, Benítez A, Sánchez-Galdón S, Dalmau B, Eraña L, Montoro M, Portu J, Garijo JM, Barniol R, Domínguez A, Rota R, Olcoz JL, Antón M, Pamplona X, Casanovas T, Jiménez E, Huarte M, Díaz F, Sánchez-Ruano J, Orive M, Muñoz-Sánchez M, Roset M. Diago M, et al. Among authors: sola r. Aliment Pharmacol Ther. 2007 Apr 15;25(8):899-906. doi: 10.1111/j.1365-2036.2007.03270.x. Aliment Pharmacol Ther. 2007. PMID: 17402993 Free article. Clinical Trial.
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
Tural C, Solà R, Rubio R, Santín M, Planas R, Quereda C, Berenguer J, Montes-Ramírez M, Clotet B; CORAL-1 study group. Tural C, et al. Among authors: sola r. J Viral Hepat. 2007 Oct;14(10):704-13. doi: 10.1111/j.1365-2893.2007.00860.x. J Viral Hepat. 2007. PMID: 17875005 Clinical Trial.
670 results